RecruitingPhase 2Phase 3NCT05689034

Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness

A Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adult Participants With COVID-19 Who Are at Increased Risk of Progressing to Severe Illness

Sponsor

Peking Union Medical College Hospital

Enrollment

1,096 participants

Start Date

Apr 19, 2023

Study Type

INTERVENTIONAL

Conditions

COVID-19 Respiratory Infection

Summary

To investigate whether treatment with Azvudine reduces the risk of severe illness or death in patients who are at a potential risk of progressing to severe COVID-19 infection.

Eligibility

Min Age: 18 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Azvudine and a drug called Placebo for people with covid-19 respiratory infection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 120 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.